Events

UPCOMING

Anavex Life Sciences to present at 3rd Annual Neuropsychiatric Drug Development Summit

Exploring Mechanistic Approaches to Treating Neuropsychiatric Disorders such as Depression, Autism & Cognitive Impairment

9:10am on Thursday, 12th of November 2020

NEWS & EVENTS

Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference

November 25, 2020

Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference
November 25, 2020

Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 Conference
November 6, 2020

Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia
October 15, 2020

Anavex Life Sciences to Present at Upcoming Global Healthcare Conferences Cantor Fitzgerald Global Healthcare Conference 2020 and H.C. Wainwright 22nd Annual Global Investment Conference
September 8, 2020

Anavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business Updates
August 6, 2020

Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73 (blarcamesine) for Alzheimer’s Disease Patients
August 5, 2020

Anavex Life Sciences to Announce Fiscal 2020 Third Quarter Financial Results on Thursday, August 6th, 2020
August 4, 2020

Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)
July 6, 2020

Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial
June 16, 2020

Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s Disease
June 4, 2020

Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)
May 21, 2020

Anavex Life Sciences Reports Fiscal 2020 Second Quarter Financial Results And Provides Business Updates
May 7, 2020

Anavex Life Sciences to Announce Fiscal 2020 Second Quarter Financial Results on Thursday, May 7th, 2020
May 5, 2020

Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19
March 31, 2020

Anavex Life Sciences to Webcast 2020 Annual Meeting of Shareholders
March 23, 2020

Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results And Provides Clinical Study Updates
February 6, 2020

Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates
December 16, 2019

Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019
December 10, 2019

Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Conference
December 4, 2019

Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome
November 14, 2019

Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease
October 9, 2019

Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’s Disease
October 2, 2019

Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
September 26, 2019

Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference
September 18, 2019

Anavex Life Sciences to Present at the Janney Healthcare Conference 2019
September 5, 2019

Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results and Provides Clinical Study Updates
August 7, 2019

Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday August 7th, 2019
August 2, 2019

Anavex Life Sciences Announces First Patient Dosed in Extension Study to its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients for Rett Syndrome
June 25, 2019

Anavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndrome (AVATAR)
June 6, 2019

Rett Syndrome Association of Australia and Anavex Life Sciences Announce Initiation of the Phase 2 AVATAR Clinical Study in Patients with Rett Syndrome
May 8, 2019

Anavex Life Sciences Reports Fiscal 2019 Second Quarter Financial Results And Provides Clinical Study Updates
May 8, 2019

Anavex Life Sciences to Announce Fiscal 2019 Second Quarter Financial Results on Wednesday May 8th, 2019
May 6, 2019

Anavex Life Sciences to Present at the H.C. Wainwright Annual Global Life Sciences Conference
April 5, 2019

Anavex Life Sciences Presents Data On ANAVEX®2-73 in Alzheimer’s Disease at the American Society for Experimental Neurotherapeutics – ASENT 2019 Annual Meeting
March 28, 2019

Anavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndrome in the U.S.
March 18, 2019

Anavex Life Sciences to Present at the 31st Annual ROTH Conference 2019
March 13, 2019

Anavex Life Sciences to Present at the Cowen 39th Annual Health Care Conference 2019
March 6, 2019

Anavex Life Sciences Reports Fiscal 2019 First Quarter Financial Results And Provides Clinical Study Updates
February 7, 2019

Anavex Life Sciences to Present at the 2019 BIO CEO & Investor Conference
February 4, 2019

Anavex Life Sciences to Announce Fiscal 2019 First Quarter Financial Results on Thursday, February 7th, 2019
January 31, 2019

Anavex Life Sciences Reports Fiscal Year 2018 Financial Results And Provides Clinical Study Update
December 12, 2018

Anavex Life Sciences to Announce 2018 Fiscal Year End Financial Results on Wednesday, December 12, 2018
December 10, 2018

Anavex Life Sciences Strengthens its Scientific Advisory Board with Distinguished Researcher for Clinical Treatment of Parkinson’s Disease Dementia (PDD)
November 8, 2018

First Patient Enrolled in Anavex Life Sciences Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson’s Disease Dementia (PDD)
October 30, 2018

Anavex Life Sciences Presents New Three-Year, Longitudinal Clinical Efficacy Data for ANAVEX®2-73 in Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
October 26, 2018

Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX®2-73 in Patients with Rett Syndrome
October 19, 2018

Anavex Life Sciences to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
September 26, 2018

First Patient Enrolled in Anavex Life Sciences Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s Disease
August 28, 2018

Anavex Life Sciences Reports Fiscal Third Quarter 2018 Financial Results
August 9, 2018

Anavex Life Sciences to Announce Fiscal Third Quarter 2018 Financial Results on Thursday, August 9, 2018
August 7, 2018

Anavex Life Sciences Presents New Data Identifying Treatment Response Biomarkers in Alzheimer’s Disease Patients Treated with Investigational ANAVEX®2-73 at 2018 Alzheimer’s Association International Conference (AAIC)
July 25, 2018

Anavex Life Sciences Receives Approval to Initiate Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson’s Disease Dementia
July 9, 2018

Anavex Life Sciences Receives Approval To Initiate Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s Disease
July 3, 2018

Anavex participates on Brain Health panel at Bio International Conference in Boston
June 5, 2018

Anavex Life Sciences Reports Fiscal Second Quarter 2018 Financial Results
May 10, 2018

Anavex Life Sciences to Announce Fiscal Second Quarter 2018 Financial Results on Thursday, May 10, 2018
May 9, 2018

Anavex Life Sciences to Initiate Phase 2 Study of ANAVEX®2-73 in Parkinson’s Disease Dementia and Provides Clinical Study Update for ANAVEX®2-73 in Rett Syndrome
April 17, 2018

Anavex Life Sciences to Present at the 30th Annual ROTH Conference
March 9, 2018

Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)
March 7, 2018

Anavex Life Sciences to Present at Cowen and Company 38th Annual Health Care Conference
March 6, 2018

Anavex Life Sciences to Present at the 2018 BIO CEO & Investor Conference
February 8, 2018

Anavex Life Sciences Provides Clinical Programs Update and Reports Fiscal First Quarter 2018 Financial Results
February 7, 2018

Anavex Life Sciences to Announce Fiscal First Quarter 2018 Financial Results and Provide an Update on Clinical Programs and Corporate Highlights on Wednesday, February 7, 2018
February 5, 2018

Anavex Life Sciences to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference
January 24, 2018

36th Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 8th-11th
January 8, 2018

Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs
December 11, 2017

5th Annual Mental health Parity Addiction Equity Act Business Roundtable in Washington DC on November 8, 2017
November 6, 2017

Anavex® Life Sciences presenting at Society for Neuroscience Nov. 11-15, 2017 in Washington DC
November 6, 2017

10th Clinical Trials on Alzheimer’s Disease CTAD November 1-4, 2017
November 4, 2017

Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017
October 27, 2017

OktoberINVESTfest on October 25th at 11AM
October 25, 2017

2017 Walk to End Alzheimer’s-Manhattan Oct 28th
October 17, 2017

Ladenburg Thalmann 2017 Healthcare Conference Sept 26 3:30pm
September 20, 2017

CNS Diseases Summit 2017 Sept 11-12
August 24, 2017

2017 Bio International Convention June 19-22
June 16, 2017

Jefferies 2017 Global Healthcare Conference June 6-9
May 30, 2017

Anavex President & CEO Christopher U. Missling, PhD, to present preclinical data on ANAVEX 2-73™ at the Epilepsy Foundation’s Antiepileptic Drug Trials XIV Conference on May 19.
May 17, 2017

Anavex President & CEO Christopher U. Missling, PhD, to participate in a roundtable discussion at the World Orphan Drug Congress USA, on April 21.
April 21, 2017

Anavex Life Sciences to Present at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases AD/PD™ 2017
March 29, 2017

Anavex Life Sciences to Present at Oppenheimer 27th Annual Healthcare Conference
March 15, 2017

Anavex Life Sciences to Present at 14th Annual BIO Asia International Conference
March 13, 2017

BIO CEO & Investor Conference 2017 Panel “Designing Clinical Trials in 21st Century Cures Paradigm”
February 9, 2017

The Noble Capital Markets’ Thirteenth Annual Investor Conference
January 30, 2017

CTAD 2016 – Clinical Trials on Alzheimer’s Disease
November 22, 2016

Maxim Group LLC – Central Nervous System Disease Conference
November 14, 2016

Global Mizuho Investor Conference (MIC)
November 11, 2016

Ladenburg Thalmann 2016 Healthcare Conference
September 20, 2016

Mizuho Therapeutics Conference
September 14, 2016

Alzheimer’s Association International Conference 2016 (AAIC) – July 24, 2016
July 12, 2016

Alzheimer’s Association International Conference 2016 (AAIC) – July 27, 2016
July 12, 2016

2016 Rett Syndrome Symposium
June 15, 2016

Speaker Session: BIO 2016 International Convention
May 3, 2016

Anavex Annual Stockholders Meeting
April 6, 2016

33rd Camerino-Cyprus Symposium
April 6, 2016

14th International Athens / Springfield Symposium on Advances in Alzheimer Therapy
February 1, 2016

2016 Epilepsy Pipeline Conference
January 15, 2016

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016
January 14, 2016

18th Annual BIO CEO & Investor Conference
January 12, 2016

American Epilepsy Society Annual Meeting
December 8, 2015

Third Annual MHPAEA Business Roundtable
December 8, 2015

ICV Manhattan 2015
December 8, 2015